H1N1										GLOBAL PANDEMICS								U.S. MONTHLY PANDEMICS
	Key symptoms	fever, chills, cough, body aches		Virus	Start	End	Duration (days)	Duraiton (months)	Duration (yrs)		Global Pop	Global Cases			Global Deaths				U.S. Pop	U.S. Cases			U.S. Deaths
												total	per-day	% pop	total	per-day	% pop			total	per-day	% pop	total	per-day	% pop
	First detection	January 2009 in Mexico; April 2009Trusted Source in United States		Spanish Flu	3/1/1918	7/31/1919	517	17	1.4		1,800,000,000	500,000,000	1,369,863	27.8%	50,000,000	136,986	2.8%		103,208,000	24,769,920	67,863	24.0%	675,000	1,849	0.7%
	Global cases	about 24 percent of global population; 60.8 million U.S. cases		SARS	11/1/2002	7/31/2003	272	9	0.7		6,301,773,188	8,098	22	0.0%	774	2	0.00%		286,100,000	0	0	0.0%	0	0	0.00%
	Global deaths	over 284,000; 12,469 in the United States; death rate was .02 percent		Ebola	12/1/2013	7/21/2022	3,154	102	8.6		7,210,581,976	28,652	78	0.0%	11,325	31	0.00%		316,200,000	0	0	0.0%	0	0	0.00%
	Most affected groups	children had the highest rates; 47 percentTrusted Source of children between 5 and 19 developed symptoms compared to 11 percent of people ages 65 and up		H1N1	1/1/2009	8/31/2010	607	20	1.7		6,872,767,093	60,800,000	166,575	0.9%	284,000	778	0.00%		300,600,000	60,000,000	164,384	20.0%	12,469	34	0.00%
	Treatment available	antiviralsTrusted Source (oseltamivir and zanamivir); most people recovered without complications		Covid-19	12/1/2019	7/21/2022	963	31	2.6		7,713,468,100	572,053,953	1,567,271	7.4%	6,414,059	17,573	0.08%		329,400,000	90,065,089	246,754	27.3%	#######	2,807	0.31%
	Vaccine available	H1N1 vaccine research started April 2009 and a vaccine became available December 2009
	End of pandemic	August 2010						How Covid-19 Compares to:			Global CASES will be:			Global DEATHS will be:					U.S. COVID-19 CASES will be:			U.S. COVID-19 DEATHS will be:
									Spanish Flu		810,279,161			8,979,683					127,571,647	38.7%		1,451,288	0.4%		<--  compared to Spanish Flu timeframe
	Vaccine available	H1N1 vaccine research started April 2009 and a vaccine became available December 2009							SARS		400,437,767			4,489,841					67,116,998	20.4%		763,541	0.2%		<-- compared to SARS timeline
	End of pandemic	August 2010							H1n1		972,491,720			#########					149,779,477	45.5%		1,703,930	0.5%		<-- compared to H1N1 timeframe
	Ebola
	Key symptoms	fever, aches and pains, weakness, diarrhea, vomiting
	First detection	first patient identified December 2013 in Guinea; first outbreak March 2014Trusted Source
	Global cases	28,652 casesTrusted Source across 10 countries
	Global deaths	11,325 deaths; death rate was about 50 percentTrusted Source
	Transmission	spread through bodily fluids (blood, sweat, feces) and close contact; most contagious toward end of disease
	Most affected groups	20 percentTrusted Source of all cases occurred in children
	Treatment available	none; supportive care was provided, including IV fluids and oral rehydration
	Vaccines available	none
	SARS
	Key symptoms	fever, respiratory symptoms, cough, malaise
	First detection	November 2002 in Guangdong province of China
	Global cases	8,098 casesTrusted Source across 29 countries; 8 U.S. cases
	Global deaths	774; 15 percent mortality rate; no U.S. deathsTrusted Source
	Transmission	spread through respiratory droplets and contaminated surfaces
	Most affected groups	patients 60 and older had a 55 percent higher death rate
	Treatment available	no treatment or cure, but antiviral medications and steroids worked for some people
	Vaccine available	a vaccine was ready around the time the pandemic was already ending
	End of pandemic	July 2003
	Spanish Flu
	Key symptoms	fever, nausea, aches, diarrhea
	First detection	March 1918
	Global cases	500 million
	Global deaths	over 50 million (675,000 in the United States); the death rate was around 2 percent
	Transmission	spread through respiratory droplets
	Most affected groups	otherwise healthy adults ages 20 to 40
	Treatments available	none; antibiotics or antivirals did not yet exist
	Vaccines available	none
	End of pandemic	summer 1919; mostly due to deaths and higher immunity levels
	Covid-19
	Key symptoms	cough, fever, shortness of breath; 80 percent of cases are mild
	First detection	December 2019 in Wuhan, China
	Global cases to date	Over 127,000 cases
	Global deaths to date	Over 4,700; the global death rate is estimated at 3.4 percentTrusted Source, but certain areas are seeing a death rate of just 0.4 percent
	Transmission	spreads through respiratory droplets along with feces and other bodily secretions; each person passes it to 2.2 others which will likely fall as containment and quarantine efforts increase
	Most affected groups	adults over 65 with underlying health conditions; children seem to be spared and are experiencing milder symptoms (in China, children account for just 2.4 percent of cases)
	Treatments available	none; supportive care is provided, pain relievers and fever reducers can alleviate symptoms, and antibiotics can help treat secondary bacterial pneumonia and antivirals used with other viruses are being administered to help with recovery
	Vaccines available	none yet; a vaccine will likely be ready in about one year